25 XP   0   0   10

Avenue Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Avenue Therapeutics Inc together

PenkeI guess you are interested in Avenue Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Avenue Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Avenue Therapeutics Inc

I send you an email if I find something interesting about Avenue Therapeutics Inc.

Quick analysis of Avenue Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Avenue Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.02
Expected worth in 1 year
$-0.05
How sure are you?
18.2%

+ What do you gain per year?

Total Gains per Share
$-0.07
Return On Investment
-45.9%

For what price can you sell your share?

Current Price per Share
$0.15
Expected price per share
$0.1125 - $0.539
How sure are you?
50%

1. Valuation of Avenue Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.15

Intrinsic Value Per Share

$-0.31 - $-0.30

Total Value Per Share

$-0.30 - $-0.28

2. Growth of Avenue Therapeutics Inc (5 min.)




Is Avenue Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$654k$1.2m-$4.2m-140.9%

How much money is Avenue Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m$223.5k-$3.1m-107.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Avenue Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#865 / 1031

Most Revenue
#877 / 1031

Most Profit
#372 / 1031

Most Efficient
#329 / 1031

What can you expect buying and holding a share of Avenue Therapeutics Inc? (5 min.)

Welcome investor! Avenue Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Avenue Therapeutics Inc.

What can you expect buying and holding a share of Avenue Therapeutics Inc?

First you should know what it really means to hold a share of Avenue Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Avenue Therapeutics Inc is $0.1526. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avenue Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avenue Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.02. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avenue Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.0211.2%-0.05-30.1%-0.05-35.7%-0.07-43.7%-0.08-53.6%
Usd Book Value Change Per Share0.1490.9%-0.02-11.5%0.00-0.8%0.001.1%0.000.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.1490.9%-0.02-11.5%0.00-0.8%0.001.1%0.000.3%
Usd Price Per Share0.16-0.80-3.00-4.46-3.72-
Price to Earnings Ratio2.35-2.36--37.61--28.79--20.03-
Price-to-Total Gains Ratio1.16--0.39--150.74--126.48--102.69-
Price to Book Ratio9.18--5.97--2,399.12--459.35--284.77-
Price-to-Total Gains Ratio1.16--0.39--150.74--126.48--102.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1526
Number of shares6553
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.00
Usd Total Gains Per Share-0.020.00
Gains per Quarter (6553 shares)-114.7011.29
Gains per Year (6553 shares)-458.8245.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-459-46904535
20-918-92809080
30-1376-13870135125
40-1835-18460181170
50-2294-23050226215
60-2753-27640271260
70-3212-32230316305
80-3671-36820361350
90-4129-41410406395
100-4588-46000451440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%2.031.00.06.1%2.031.00.06.1%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.015.00.025.0%6.025.02.018.2%6.025.02.018.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%5.015.00.025.0%6.025.02.018.2%6.025.02.018.2%

Fundamentals of Avenue Therapeutics Inc

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Fundamental data was last updated by Penke on 2024-03-20 10:39:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Avenue Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Avenue Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avenue Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Avenue Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • 34.6% Return on Assets means that Avenue Therapeutics Inc generated $0.35 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avenue Therapeutics Inc:

  • The MRQ is 34.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -51.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ34.6%TTM-51.1%+85.7%
TTM-51.1%YOY-61.9%+10.8%
TTM-51.1%5Y-50.0%-1.1%
5Y-50.0%10Y-2,366.5%+2,316.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.6%-12.5%+47.1%
TTM-51.1%-12.2%-38.9%
YOY-61.9%-11.2%-50.7%
5Y-50.0%-13.3%-36.7%
10Y-2,366.5%-14.6%-2,351.9%
1.1.3. Return on Equity

Shows how efficient Avenue Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • 40.5% Return on Equity means Avenue Therapeutics Inc generated $0.40 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avenue Therapeutics Inc:

  • The MRQ is 40.5%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 10.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ40.5%TTM10.1%+30.3%
TTM10.1%YOY-54.7%+64.8%
TTM10.1%5Y-38.3%+48.4%
5Y-38.3%10Y-33.8%-4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ40.5%-16.0%+56.5%
TTM10.1%-15.8%+25.9%
YOY-54.7%-13.9%-40.8%
5Y-38.3%-18.2%-20.1%
10Y-33.8%-19.1%-14.7%

1.2. Operating Efficiency of Avenue Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Avenue Therapeutics Inc is operating .

  • Measures how much profit Avenue Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avenue Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Avenue Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of Avenue Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Avenue Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.55 means the company has $1.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 1.547. The company is able to pay all its short-term debts. +1
  • The TTM is 0.664. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ1.547TTM0.664+0.883
TTM0.664YOY1.943-1.279
TTM0.6645Y3.397-2.733
5Y3.39710Y3.082+0.315
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5473.987-2.440
TTM0.6644.440-3.776
YOY1.9435.569-3.626
5Y3.3976.158-2.761
10Y3.0826.492-3.410
1.3.2. Quick Ratio

Measures if Avenue Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.49 means the company can pay off $1.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 1.491. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 0.627. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.491TTM0.627+0.864
TTM0.627YOY1.679-1.052
TTM0.6275Y3.544-2.917
5Y3.54410Y3.454+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4913.653-2.162
TTM0.6274.158-3.531
YOY1.6795.515-3.836
5Y3.5446.012-2.468
10Y3.4546.206-2.752

1.4. Solvency of Avenue Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Avenue Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Avenue Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65 means that Avenue Therapeutics Inc assets are financed with 64.6% credit (debt) and the remaining percentage (100% - 64.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.646. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 4.150. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ0.646TTM4.150-3.503
TTM4.150YOY0.601+3.549
TTM4.1505Y1.138+3.011
5Y1.13810Y53.891-52.753
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6460.336+0.310
TTM4.1500.330+3.820
YOY0.6010.267+0.334
5Y1.1380.367+0.771
10Y53.8910.378+53.513
1.4.2. Debt to Equity Ratio

Measures if Avenue Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 75.6% means that company has $0.76 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.756. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.189. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.756TTM0.189+0.567
TTM0.189YOY0.571-0.382
TTM0.1895Y0.330-0.141
5Y0.33010Y0.288+0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7560.376+0.380
TTM0.1890.398-0.209
YOY0.5710.334+0.237
5Y0.3300.431-0.101
10Y0.2880.476-0.188

2. Market Valuation of Avenue Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Avenue Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Avenue Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 2.35 means the investor is paying $2.35 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avenue Therapeutics Inc:

  • The EOD is 2.224. Based on the earnings, the company is cheap. +2
  • The MRQ is 2.346. Based on the earnings, the company is cheap. +2
  • The TTM is 2.362. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.224MRQ2.346-0.122
MRQ2.346TTM2.362-0.016
TTM2.362YOY-37.609+39.971
TTM2.3625Y-28.788+31.149
5Y-28.78810Y-20.032-8.756
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.224-2.697+4.921
MRQ2.346-2.422+4.768
TTM2.362-2.709+5.071
YOY-37.609-4.116-33.493
5Y-28.788-6.257-22.531
10Y-20.032-6.478-13.554
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avenue Therapeutics Inc:

  • The EOD is 2.105. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.221. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -2.453. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.105MRQ2.221-0.116
MRQ2.221TTM-2.453+4.675
TTM-2.453YOY-44.319+41.866
TTM-2.4535Y-43.485+41.032
5Y-43.48510Y-32.824-10.661
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.105-3.344+5.449
MRQ2.221-2.939+5.160
TTM-2.453-3.486+1.033
YOY-44.319-5.592-38.727
5Y-43.485-8.464-35.021
10Y-32.824-8.872-23.952
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Avenue Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.18 means the investor is paying $9.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avenue Therapeutics Inc:

  • The EOD is 8.705. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.184. Based on the equity, the company is overpriced. -1
  • The TTM is -5.975. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.705MRQ9.184-0.479
MRQ9.184TTM-5.975+15.159
TTM-5.975YOY-2,399.116+2,393.141
TTM-5.9755Y-459.348+453.373
5Y-459.34810Y-284.773-174.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.7052.198+6.507
MRQ9.1842.042+7.142
TTM-5.9752.121-8.096
YOY-2,399.1162.907-2,402.023
5Y-459.3483.682-463.030
10Y-284.7734.114-288.887
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avenue Therapeutics Inc.

3.1. Institutions holding Avenue Therapeutics Inc

Institutions are holding 3.316% of the shares of Avenue Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Geode Capital Management, LLC0.1398052160-411-0.7818
2023-12-31Vanguard Group Inc0.124104629300
2023-12-31State Street Corporation0.08203059300
2023-12-31Millennium Management LLC0.0767028605286050
2023-12-31TWO SIGMA SECURITIES, LLC0.07370275001306290.4696
2023-12-31HRT FINANCIAL LLC0.0678025283252830
2023-12-31Cubist Systematic Strategies, LLC0.0292010909109090
2023-12-31Tower Research Capital LLC0.018306814-62-0.9017
2023-12-31Wells Fargo & Co0.012404624390.8506
2023-12-31BlackRock Inc0.003401257-611-32.7088
2023-12-31UBS Group AG0.00290108010800
2023-12-31EMFO, LLC0.00140.000153300
2023-12-31Royal Bank of Canada0.00140514416424.4898
2023-12-31BARRETT & COMPANY, INC.001500
2023-09-30Sabby Management LLC000-553338-100
2023-12-31Bank of New York Mellon Corp000-51572-100
2023-12-31Shikiar Asset Management Inc000-12500-100
2023-12-31Morgan Stanley - Brokerage Accounts000-276-100
2023-12-31Advisor Group Holdings, Inc.000-500-100
Total 0.63310.0001236180-539876-228.6%

3.2. Funds holding Avenue Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.124104629300
2024-01-31Fidelity Extended Market Index0.119704465200
2024-01-31Fidelity Series Total Market Index0.01670623600
2024-01-31Fidelity Nasdaq Composite Index0.00340127200
2023-09-30BlackRock Extended Mkt Composite0.00340125700
2023-12-31BlackRock Extended Equity Market K0.002901097-2-0.182
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0012046600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.001038400
2023-12-31Northern Trust Extended Eq Market Idx0.001038400
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.001037410.2681
2023-12-31SSgA U.S. Extended Market Index Class I0.0005019300
2024-02-29State St US Extended Mkt Indx NL Cl C0.0005019300
2023-12-31Extended Equity Market Fund M0.0004013664.6154
2023-12-31Northern Trust Wilshire 50000.000206000
2023-12-31NT US Market Cap Idx Fd - L0.000206000
2023-12-31SSgA U.S. Total Market Index Strategy0.0002056-1-1.7544
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 5001500
Total 0.27640103128+4+0.0%

3.3. Insider Transactions

Insiders are holding 12.907% of the shares of Avenue Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-08Fortress Biotech, Inc.BUY4184100.72
2023-09-08Lindsay A Md RosenwaldBUY3486750.72

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Avenue Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.139-0.018+113%-0.001+101%0.002+7956%0.001+26017%
Book Value Per Share--0.018-0.082+565%0.033-48%0.089-80%0.093-81%
Current Ratio--1.5470.664+133%1.943-20%3.397-54%3.082-50%
Debt To Asset Ratio--0.6464.150-84%0.601+8%1.138-43%53.891-99%
Debt To Equity Ratio--0.7560.189+300%0.571+32%0.330+129%0.288+162%
Dividend Per Share----0%-0%-0%-0%
Eps--0.017-0.046+368%-0.055+418%-0.067+489%-0.082+577%
Free Cash Flow Per Share--0.018-0.063+450%-0.051+381%-0.069+482%-0.064+453%
Free Cash Flow To Equity Per Share--0.124-0.013+110%0.018+583%0.016+694%0.009+1288%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.296--------
Intrinsic Value_10Y_min---0.313--------
Intrinsic Value_1Y_max---0.163--------
Intrinsic Value_1Y_min---0.161--------
Intrinsic Value_3Y_max---0.389--------
Intrinsic Value_3Y_min---0.374--------
Intrinsic Value_5Y_max---0.492--------
Intrinsic Value_5Y_min---0.465--------
Market Cap5692804.040-6%6006169.40029872299.050-80%111830397.580-95%166516010.386-96%138687685.507-96%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio8.705-6%9.184-5.975+165%-2399.116+26224%-459.348+5102%-284.773+3201%
Pe Ratio2.224-6%2.3462.362-1%-37.609+1703%-28.788+1327%-20.032+954%
Price Per Share0.153-6%0.1610.801-80%2.998-95%4.464-96%3.718-96%
Price To Free Cash Flow Ratio2.105-6%2.221-2.453+210%-44.319+2095%-43.485+2058%-32.824+1578%
Price To Total Gains Ratio1.100-6%1.160-0.389+134%-150.745+13091%-126.479+11000%-102.690+8950%
Quick Ratio--1.4910.627+138%1.679-11%3.544-58%3.454-57%
Return On Assets--0.346-0.511+248%-0.619+279%-0.500+245%-23.665+6941%
Return On Equity--0.4050.101+300%-0.547+235%-0.383+195%-0.338+184%
Total Gains Per Share--0.139-0.018+113%-0.001+101%0.002+7956%0.001+26017%
Usd Book Value--654000.000-3042750.000+565%1246000.000-48%3335200.000-80%3451424.242-81%
Usd Book Value Change Per Share--0.139-0.018+113%-0.001+101%0.002+7956%0.001+26017%
Usd Book Value Per Share--0.018-0.082+565%0.033-48%0.089-80%0.093-81%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.017-0.046+368%-0.055+418%-0.067+489%-0.082+577%
Usd Free Cash Flow--676000.000-2362750.000+450%-1899000.000+381%-2583450.000+482%-2384818.182+453%
Usd Free Cash Flow Per Share--0.018-0.063+450%-0.051+381%-0.069+482%-0.064+453%
Usd Free Cash Flow To Equity Per Share--0.124-0.013+110%0.018+583%0.016+694%0.009+1288%
Usd Market Cap5692804.040-6%6006169.40029872299.050-80%111830397.580-95%166516010.386-96%138687685.507-96%
Usd Price Per Share0.153-6%0.1610.801-80%2.998-95%4.464-96%3.718-96%
Usd Profit--640000.000-2887500.000+551%223500.000+186%-2272300.000+455%-2670608.788+517%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.139-0.018+113%-0.001+101%0.002+7956%0.001+26017%
 EOD+4 -4MRQTTM+23 -6YOY+16 -135Y+17 -1210Y+17 -12

4.2. Fundamental Score

Let's check the fundamental score of Avenue Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-152.224
Price to Book Ratio (EOD)Between0-18.705
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.491
Current Ratio (MRQ)Greater than11.547
Debt to Asset Ratio (MRQ)Less than10.646
Debt to Equity Ratio (MRQ)Less than10.756
Return on Equity (MRQ)Greater than0.150.405
Return on Assets (MRQ)Greater than0.050.346
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Avenue Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.879
Ma 20Greater thanMa 500.162
Ma 50Greater thanMa 1000.151
Ma 100Greater thanMa 2000.168
OpenGreater thanClose0.155
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,850
Total Liabilities1,196
Total Stockholder Equity1,582
 As reported
Total Liabilities 1,196
Total Stockholder Equity+ 1,582
Total Assets = 1,850

Assets

Total Assets1,850
Total Current Assets1,850
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 1,783
Other Current Assets 67
Total Current Assets  (as reported)1,850
Total Current Assets  (calculated)1,850
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,196
Long-term Liabilities0
Total Stockholder Equity1,582
Total Current Liabilities
Accounts payable 401
Other Current Liabilities 795
Total Current Liabilities  (as reported)1,196
Total Current Liabilities  (calculated)1,196
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -90,928
Other Stockholders Equity 92,507
Total Stockholder Equity (as reported)1,582
Total Stockholder Equity (calculated)1,582
+/-0
Other
Capital Stock3
Cash and Short Term Investments 1,783
Common Stock Shares Outstanding 25,598
Liabilities and Stockholders Equity 1,850
Net Debt -1,783
Net Invested Capital 1,582
Net Working Capital 654



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
10
0
0
60
197
234
34,705
26,176
22,170
15,273
9,436
5,263
4,525
29,763
15,677
13,878
8,915
6,696
5,331
4,352
3,245
1,944
1,191
688
3,960
1,956
1,005
575
6,845
8,447
1,666
502
1,850
1,8505021,6668,4476,8455751,0051,9563,9606881,1911,9443,2454,3525,3316,6968,91513,87815,67729,7634,5255,2639,43615,27322,17026,17634,705234197600010
   > Total Current Assets 
10
0
0
60
197
234
34,705
26,176
22,170
15,273
9,436
5,263
4,525
29,763
15,677
13,878
8,915
6,696
5,331
4,352
3,245
1,944
1,191
688
3,960
1,956
1,005
575
6,845
8,447
1,666
502
1,850
1,8505021,6668,4476,8455751,0051,9563,9606881,1911,9443,2454,3525,3316,6968,91513,87815,67729,7634,5255,2639,43615,27322,17026,17634,705234197600010
       Cash And Cash Equivalents 
10
0
0
30
197
0
34,683
16,050
11,782
14,963
8,940
4,804
2,671
29,448
10,455
8,741
8,745
6,574
5,257
4,325
3,132
1,825
1,121
585
3,763
1,833
890
217
6,708
8,236
1,571
161
1,783
1,7831611,5718,2366,7082178901,8333,7635851,1211,8253,1324,3255,2576,5748,7458,74110,45529,4482,6714,8048,94014,96311,78216,05034,6830197300010
       Short-term Investments 
0
0
0
0
0
0
0
10,000
10,000
10,000
0
0
0
0
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000005,0005,000000010,00010,00010,0000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
90
0
0
0
0
13
26
13
0
01326130000907400000000000000000000000
       Other Current Assets 
0
0
0
30
0
234
22
126
388
310
496
459
152
254
161
76
170
122
74
27
113
119
70
29
197
123
115
358
137
198
69
18
67
671869198137358115123197297011911327741221707616125415245949631038812622234030000
   > Long-term Assets 
0
0
0
0
0
0
0
0
388
0
0
0
1,854
61
61
61
170
0
0
0
113
0
0
0
0
0
0
338
137
0
0
310
0
0310001373380000001130001706161611,85400038800000000
       Other Assets 
0
0
0
0
0
234
22
126
-388
310
496
459
-1,854
315
222
137
-170
122
74
27
-113
119
70
688
0
123
115
-338
-137
211
95
-310
0
0-31095211-137-338115123068870119-1132774122-170137222315-1,854459496310-3881262223400000
> Total Liabilities 
5,150
0
0
7,550
8,445
9,138
7,549
1,990
2,790
5,920
4,419
2,469
5,156
9,412
1,773
1,917
2,115
923
1,230
1,118
886
469
549
848
509
797
407
614
3,579
10,604
7,812
5,024
1,196
1,1965,0247,81210,6043,5796144077975098485494698861,1181,2309232,1151,9171,7739,4125,1562,4694,4195,9202,7901,9907,5499,1388,4457,550005,150
   > Total Current Liabilities 
2,450
0
0
4,760
6,419
7,825
7,155
1,990
2,790
5,920
4,419
2,469
5,156
9,412
1,773
1,917
2,115
923
1,230
1,118
886
469
549
848
509
797
407
614
3,579
10,604
7,812
5,024
1,196
1,1965,0247,81210,6043,5796144077975098485494698861,1181,2309232,1151,9171,7739,4125,1562,4694,4195,9202,7901,9907,1557,8256,4194,760002,450
       Short-term Debt 
3,868
0
0
0
3,848
4,669
5,986
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000005,9864,6693,8480003,868
       Short Long Term Debt 
3,868
0
0
0
1,000
2,061
6,380
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000006,3802,0611,0000003,868
       Accounts payable 
491
0
0
0
506
868
826
1,990
2,737
4,076
3,379
1,141
3,576
7,345
896
1,901
368
350
216
430
172
218
215
378
362
544
303
405
150
1,838
446
1,460
401
4011,4604461,8381504053035443623782152181724302163503681,9018967,3453,5761,1413,3794,0762,7371,990826868506000491
       Other Current Liabilities 
2,450
0
0
4,760
314
311
343
0
53
1,844
1,040
1,328
1,580
2,067
877
16
1,747
573
1,014
688
714
251
334
470
147
253
104
209
3,429
8,766
7,366
3,564
795
7953,5647,3668,7663,4292091042531474703342517146881,0145731,747168772,0671,5801,3281,0401,8445303433113144,760002,450
   > Long-term Liabilities 
2,700
0
0
2,790
2,026
1,313
394
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
362
544
397
405
949
1,838
0
0
0
0001,838949405397544362000000000000000003941,3132,0262,790002,700
       Long term Debt Total 
0
0
0
0
0
1,313
394
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000003941,31300000
       Long term Debt 
2,703
0
0
0
2,026
1,313
394
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000003941,3132,0260002,703
> Total Stockholder Equity
-5,140
0
0
-7,490
-8,248
-8,904
27,156
24,186
19,380
9,353
5,017
2,794
-631
20,351
13,904
11,961
6,800
5,773
4,101
3,234
2,359
1,475
642
-160
3,451
1,159
598
-39
3,905
-1,452
-5,336
-3,650
1,582
1,582-3,650-5,336-1,4523,905-395981,1593,451-1606421,4752,3593,2344,1015,7736,80011,96113,90420,351-6312,7945,0179,35319,38024,18627,156-8,904-8,248-7,49000-5,140
   Common Stock
40
0
0
0
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
0
0
1
1
1
3
3111002222222222222211111111100040
   Retained Earnings -90,928-91,568-92,094-88,087-80,551-81,126-80,464-79,860-76,999-76,086-75,215-74,266-73,268-72,275-71,247-69,359-68,117-62,702-60,460-53,478-42,209-38,290-35,695-31,038-20,661-14,418-11,470-9,064-8,403-7,59000-5,230
   Capital Surplus 
0
0
0
0
0
159
38,625
38,603
38,937
40,390
40,711
41,083
41,577
73,827
74,362
74,661
74,915
75,130
75,346
75,507
75,625
75,739
75,855
0
0
0
0
0
0
0
0
0
0
000000000075,85575,73975,62575,50775,34675,13074,91574,66174,36273,82741,57741,08340,71140,39038,93738,60338,62515900000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
50
0
0
100
154
159
38,625
38,603
40,040
40,390
40,711
41,083
41,577
73,827
74,362
74,661
74,915
75,130
75,346
75,507
75,625
75,739
75,855
75,924
80,448
81,017
81,060
81,087
84,456
86,634
86,757
87,917
92,507
92,50787,91786,75786,63484,45681,08781,06081,01780,44875,92475,85575,73975,62575,50775,34675,13074,91574,66174,36273,82741,57741,08340,71140,39040,04038,60338,6251591541000050



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-14,540
Operating Income-14,540-14,540
 
Operating Expense (+$)
Research Development10,361
Selling General Administrative4,179
Selling And Marketing Expenses0
Operating Expense14,54014,540
 
Net Interest Income (+$)
Interest Income126
Interest Expense-332
Other Finance Cost-0
Net Interest Income-206
 
Pretax Income (+$)
Operating Income-14,540
Net Interest Income-206
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,488-18,592
EBIT - interestExpense = -332
-10,488
-10,045
Interest Expense332
Earnings Before Interest and Taxes (EBIT)0-10,156
Earnings Before Interest and Taxes (EBITDA)-14,540
 
After tax Income (+$)
Income Before Tax-10,488
Tax Provision-0
Net Income From Continuing Ops-10,488-10,488
Net Income-10,377
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses14,540
Total Other Income/Expenses Net4,052206
 

Technical Analysis of Avenue Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Avenue Therapeutics Inc. The general trend of Avenue Therapeutics Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Avenue Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Avenue Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.2 < 0.3529 < 0.539.

The bearish price targets are: 0.132 > 0.1125.

Tweet this
Avenue Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Avenue Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Avenue Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Avenue Therapeutics Inc. The current macd is -0.00053106.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avenue Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Avenue Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Avenue Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Avenue Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAvenue Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Avenue Therapeutics Inc. The current adx is 14.78.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Avenue Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Avenue Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Avenue Therapeutics Inc. The current sar is 0.17840545.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Avenue Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Avenue Therapeutics Inc. The current rsi is 46.88. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Avenue Therapeutics Inc Daily Relative Strength Index (RSI) ChartAvenue Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Avenue Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avenue Therapeutics Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Avenue Therapeutics Inc Daily Stochastic Oscillator ChartAvenue Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Avenue Therapeutics Inc. The current cci is -89.06202261.

Avenue Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAvenue Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Avenue Therapeutics Inc. The current cmo is -11.61129789.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Avenue Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAvenue Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Avenue Therapeutics Inc. The current willr is -79.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Avenue Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Avenue Therapeutics Inc Daily Williams %R ChartAvenue Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Avenue Therapeutics Inc.

Avenue Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Avenue Therapeutics Inc. The current atr is 0.01532789.

Avenue Therapeutics Inc Daily Average True Range (ATR) ChartAvenue Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Avenue Therapeutics Inc. The current obv is 407,187,018.

Avenue Therapeutics Inc Daily On-Balance Volume (OBV) ChartAvenue Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Avenue Therapeutics Inc. The current mfi is 51.57.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Avenue Therapeutics Inc Daily Money Flow Index (MFI) ChartAvenue Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Avenue Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Avenue Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Avenue Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.879
Ma 20Greater thanMa 500.162
Ma 50Greater thanMa 1000.151
Ma 100Greater thanMa 2000.168
OpenGreater thanClose0.155
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Avenue Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Avenue Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Avenue Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Avenue Therapeutics Inc

I send you an email if I find something interesting about Avenue Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Avenue Therapeutics Inc.

Receive notifications about Avenue Therapeutics Inc in your mailbox!